European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform
"The issuance of this patent further expands a series of worldwide patents protecting our proprietary, highly sensitive ctDNA platform technology into several key European countries, which we believe could be important markets for our liquid biopsy tests," said
The recently granted European patent encompasses
"Obtaining this patent provides additional intellectual property protection for the unique and novel features of our Target Selector™ liquid biopsy platform used for ctDNA analysis," stated
About
The "switch-blocker" technology covered by European Patent No. 2,705,162 further expands on U.S. Patent No. 9,834,817, Chinese Patent No. ZL201280032293.0 and Australian Patent No. 2012250516, that are applicable to a broad range of molecular genomic platforms, including real-time PCR, digital PCR,
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the utility and effectiveness of our intellectual property protections, our ability to expand the adoption of our tests globally, and the cost saving attributes of our switch-blocker technology, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/european-patent-granted-for-biocepts-target-selector-oncogene-mutation-enrichment-and-detection-platform-300688936.html
SOURCE
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100 Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109